KIDNEY
Treating Kidney Cancer with Cryoablation
Cryoablation for kidney tumors is a fast, safe and effective minimally invasive procedure providing an additional treatment option to higher-risk surgical interventions. Using CT imaging, a small cryoprobe (like a thin hollow needle) is guided into the tumor and the ice ball growth is monitored. Extremely cold temperatures are applied to freeze and destroy the benign or cancerous tissue.
ProSense’s minimally invasive cryoablation procedure provides patients and physicians with an improved treatment experience with minimal pain, reduced scarring, and accelerated recovery.
- Rapid recovery: One day of hospital stay on average, helping lower hospital costs with some patients able to go home that same day
- Short procedure: Up to 2 hours for a cryoablation procedure helping save physicians time and reduce waiting times (surgery is typically 2- 6 hours)
- Minimal pain and discomfort: Cooling from the cryoablation itself reduces pain
- Can be performed under light sedation: Eliminates risks from general anesthesia required during surgery
- Works alongside existing chemotherapy, surgical resection, SBRT, or immunotherapy
- Repeatable procedure: Allows for further treatment and potentially reduces the impact of higher local recurrence after a single ablation
- Easy to use and efficient: Powerful liquid nitrogen freezing without gas line restrictions, user friendly touch screen system and unique single cryoprobe system helps saves time and cost
How effective is cryoablation for kidney cancer?
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Cryoablation is considered a safe and effective treatment option for small kidney lesions.[3]
Interim results from a clinical trial (ICE-SECRET) with IceCure’s ProSense™ liquid-nitrogen system demonstrated percutaneous cryoablation for early-stage (T1a) small renal masses (SRMs) was a feasible and safe procedure, with minimal adverse effects and similar oncologic results as Nephron Sparing Surgery (NSS).
At 1 year follow-up of 42 patients with ≤4cm renal masses from 74 patients involved in the trial, results demonstrated:
- 93% of patients were recurrence free
- 92% of patients had no adverse effects.
Patient selection
Cryoablation represents an alternative treatment approach for patients diagnosed with kidney cancer. Before undergoing the procedure, a healthcare professional will order an MRI or CT scan to ensure that an individual is a suitable candidate for the procedure.
Typically, patients who have stage T1a or T1b kidney cancer are suitable. Age, kidney function, location and size of the tumor will affect whether cryoablation is suitable.
Based on National Comprehensive Cancer Network (NCCN) guidelines, cryoablation is best suited for treating small renal masses of ≤4cm in patients who are:
- not suitable for surgery
- following a partial nephrectomy
- with a single or transplanted kidney.